Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N. Nagai T, et al. Among authors: kanakura y. Int J Hematol. 2010 Jul;92(1):111-7. doi: 10.1007/s12185-010-0621-x. Epub 2010 Jun 25. Int J Hematol. 2010. PMID: 20577839 Clinical Trial.
Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Ozawa K, Omine M. Kanakura Y, et al. Int J Hematol. 2013 Oct;98(4):406-16. doi: 10.1007/s12185-013-1404-y. Epub 2013 Aug 11. Int J Hematol. 2013. PMID: 23934275 Clinical Trial.
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits.
Nakamae H, Yoshida C, Miyata Y, Hidaka M, Uike N, Koga D, Sogabe T, Matsumura I, Kanakura Y, Naoe T. Nakamae H, et al. Among authors: kanakura y. Int J Hematol. 2015 Sep;102(3):304-11. doi: 10.1007/s12185-015-1826-9. Epub 2015 Jul 4. Int J Hematol. 2015. PMID: 26141653 Clinical Trial.
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
Ishiyama K, Nakao S, Usuki K, Yonemura Y, Ikezoe T, Uchiyama M, Mori Y, Fukuda T, Okada M, Fujiwara SI, Noji H, Rottinghaus S, Aguzzi R, Yokosawa J, Nishimura JI, Kanakura Y, Okamoto S. Ishiyama K, et al. Among authors: kanakura y. Int J Hematol. 2020 Oct;112(4):466-476. doi: 10.1007/s12185-020-02934-6. Epub 2020 Aug 31. Int J Hematol. 2020. PMID: 32869125 Clinical Trial.
Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, Shichishima T, Okamoto S, Nishimura JI, Ohyashiki K, Nakao S, Ando K, Kanda Y, Kawaguchi T, Nakakuma H, Harada D, Akiyama H, Kinoshita T, Ozawa K, Omine M, Kanakura Y. Ninomiya H, et al. Among authors: kanakura y. Int J Hematol. 2016 Nov;104(5):548-558. doi: 10.1007/s12185-016-2065-4. Epub 2016 Jul 27. Int J Hematol. 2016. PMID: 27464489
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Kanakura Y, et al. Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12. Int J Hematol. 2011. PMID: 21222185 Clinical Trial.
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y. Nagafuji K, et al. Among authors: kanakura y. Int J Hematol. 2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. Epub 2019 Sep 19. Int J Hematol. 2019. PMID: 31538327 Clinical Trial.
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes. Kobayashi T, et al. Among authors: kanakura y. Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905. Epub 2017 Sep 28. Am J Hematol. 2017. PMID: 28891083 Free article.
Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.
Miyakawa Y, Katsutani S, Yano T, Nomura S, Nishiwaki K, Tomiyama Y, Higashihara M, Shirasugi Y, Nishikawa M, Ozaki K, Abe T, Kikuchi K, Kanakura Y, Fujimura K, Ikeda Y, Okamoto S. Miyakawa Y, et al. Among authors: kanakura y. Int J Hematol. 2015 Dec;102(6):654-61. doi: 10.1007/s12185-015-1887-9. Int J Hematol. 2015. PMID: 26466831 Clinical Trial.
421 results